Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential

Jimin Xu, Pei Yong Shi, Hongmin Li, Jia Zhou

Research output: Contribution to journalReview articlepeer-review

91 Scopus citations


The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.

Original languageEnglish (US)
Pages (from-to)909-915
Number of pages7
JournalACS Infectious Diseases
Issue number5
StatePublished - May 8 2020


  • Ebola virus
  • MERS-CoV
  • SARS-CoV
  • SARS-CoV-2 (COVID-19)
  • Zika virus
  • broad antiviral agents
  • coronavirus
  • flavivirus
  • human adenovirus
  • niclosamide

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential'. Together they form a unique fingerprint.

Cite this